Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of atezolizumab, bevacizumab, and aspirin in recurrent platinum-resistant ovarian cancer
NL-OMON50342Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atezolizumab, bevacizumab and aspirin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal adenocarcinoma (PPC) (5 arms), sponsored by Radboud University Medical Center. Primary endpoints: Progression-free survival at 6 months and Safety. Started May 2018; status: active, not recruiting.
02
Drugs
atezolizumabbevacizumabaspirin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal adenocarcinoma (PPC)
Beyond the preview
Go deeper on NL-OMON50342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50342.